Cite
Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.
MLA
Giani, Marisa, et al. “Alport Syndrome: The Effects of Spironolactone on Proteinuria and Urinary TGF-Β1.” Pediatric Nephrology (Berlin, Germany), vol. 28, no. 9, Sept. 2013, pp. 1837–42. EBSCOhost, https://doi.org/10.1007/s00467-013-2490-z.
APA
Giani, M., Mastrangelo, A., Villa, R., Turolo, S., Marra, G., Tirelli, A. S., Hopfer, H., & Edefonti, A. (2013). Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1. Pediatric Nephrology (Berlin, Germany), 28(9), 1837–1842. https://doi.org/10.1007/s00467-013-2490-z
Chicago
Giani, Marisa, Antonio Mastrangelo, Roberta Villa, Stefano Turolo, Giuseppina Marra, Amedea Silvia Tirelli, Helmut Hopfer, and Alberto Edefonti. 2013. “Alport Syndrome: The Effects of Spironolactone on Proteinuria and Urinary TGF-Β1.” Pediatric Nephrology (Berlin, Germany) 28 (9): 1837–42. doi:10.1007/s00467-013-2490-z.